JGC
HZNP

J. Goldman & Co’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

J. Goldman & Co’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-221,000
Closed -$4.01M – 435
2016
Q3 		$4.01M Buy
+221,000
New +$4.32M 0.23% 128

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

J. Goldman & Co's HZNP Position: Q3 2022 in Review

J. Goldman & Co sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2022, closing a stake of 37,761 shares — an estimated $3.01M sold.

J. Goldman & Co first reported a position in HZNP in Q3 2013 and held it in 8 quarters. The position peaked at $5.09M in Q4 2013. 530 funds tracked by Wall St. Rank hold HZNP as of Q3 2022.

  • J. Goldman & Co reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2022 after selling out during the quarter.
  • J. Goldman & Co sold 37,761 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2022, an estimated $3.01M.
  • J. Goldman & Co first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2013 and held it in 8 quarters.
  • J. Goldman & Co's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $5.09M in Q4 2013.
  • 530 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2022.

Based on J. Goldman & Co's 13F filing for Q3 2022, filed 14 Nov 2022.